158 related articles for article (PubMed ID: 37951494)
21. Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients.
Heemelaar JC; Speetjens FM; Al Jaff AAM; Evenhuis RE; Polomski EAS; Mertens BJA; Jukema JW; Gelderblom H; van de Sande MAJ; Antoni ML
JACC CardioOncol; 2023 Feb; 5(1):117-127. PubMed ID: 36875898
[TBL] [Abstract][Full Text] [Related]
22. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
24. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
26. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
27. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
28. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
29. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
30. Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe: Results From the BiomarCaRE Consortium.
Magnussen C; Niiranen TJ; Ojeda FM; Gianfagna F; Blankenberg S; Vartiainen E; Sans S; Pasterkamp G; Hughes M; Costanzo S; Donati MB; Jousilahti P; Linneberg A; Palosaari T; de Gaetano G; Bobak M; den Ruijter HM; Jørgensen T; Söderberg S; Kuulasmaa K; Zeller T; Iacoviello L; Salomaa V; Schnabel RB;
JACC Heart Fail; 2019 Mar; 7(3):204-213. PubMed ID: 30819375
[TBL] [Abstract][Full Text] [Related]
31. Importance of familial predisposition to heart failure to the risk of anthracycline-related cardiotoxicity: A nationwide study.
Banke A; Andersson C; D'Souza M; Fosbøl E; Nielsen D; Pedersen CT; Gislason GH; Møller JE; Køber L; Rasmussen CM; Schou M
Am Heart J; 2023 Nov; 265():59-65. PubMed ID: 37453730
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Five-Year Retrospective Study in 10 Centers.
Gerodias FR; Tan MK; De Guzman A; Bernan A; Locnen SA; Apostol-Alday A; Ybanez EJ; Magno JD; Lim A; Junia A; Mambulao R; Cosare-San Pedro J; Lucero J; Quijano Z; Apurillo J; Uson AJ; Lim JL; Inso CA; Agoncillo-Infante A; Bongcawil RY; Fernando GY; Ramos-Manalaysay AM; Arellano-Simon FA; Ilagan-Cargullo EM; Bago-Azares MJ; Baterna J; Tapispisan JA; Masadao-Rodriguez NM; Tarranza JL; Lista LS; Gumapon JK
Cardiol Res; 2022 Dec; 13(6):380-392. PubMed ID: 36660064
[TBL] [Abstract][Full Text] [Related]
33. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
35. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
36. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
Banke A; Fosbøl EL; Møller JE; Gislason GH; Andersen M; Bernsdorf M; Jensen MB; Schou M; Ejlertsen B
Eur J Heart Fail; 2018 Oct; 20(10):1447-1453. PubMed ID: 29493047
[TBL] [Abstract][Full Text] [Related]
37. Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases.
Lassalle M; Colas S; Rudnichi A; Zureik M; Dray-Spira R
Clin Orthop Relat Res; 2018 Jul; 476(7):1441-1451. PubMed ID: 29698302
[TBL] [Abstract][Full Text] [Related]
38. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience.
Fornaro A; Olivotto I; Rigacci L; Ciaccheri M; Tomberli B; Ferrantini C; Coppini R; Girolami F; Mazzarotto F; Chiostri M; Milli M; Marchionni N; Castelli G
Eur J Heart Fail; 2018 May; 20(5):898-906. PubMed ID: 29148208
[TBL] [Abstract][Full Text] [Related]
39. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
Wilcox NS; Rotz SJ; Mullen M; Song EJ; Ky Hamilton B; Moslehi J; Armenian SH; Wu JC; Rhee JW; Ky B
Circ Res; 2022 Feb; 130(4):632-651. PubMed ID: 35175846
[TBL] [Abstract][Full Text] [Related]
40. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
